ExpressPoints: Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates

Download this short summary slideset of key takeaways from a live CCO Webinar focused on monitoring and management of ocular toxicity in patients with cancer receiving antibody-drug conjugate therapy.
Asim V. Farooq, MD
Anthony Perissinotti, PharmD, BCOP
Format: Microsoft PowerPoint (.ppt)
File Size: 265 KB
Released: December 18, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Related Content

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Drs. Amy DeZern and Srdan Verstovsek discuss their top abstract choices from ASH 2020 in MDS and MPNs, from Clinical Care Options (CCO)

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue